Practical recommendations for systemic treatment in psoriasis in case of coexisting inflammatory, neurologic, infectious, or malignant disorders (BETA-PSO: Belgian Evidence-based Treatment Advice in Psoriasis; part 2)
Lambert, J.L.W; Segaert, S.; Ghislain, P.Det al.
2020 • In Journal of the European Academy of Dermatology and Venereology
Psoriasis; Inflammatory, neurologic, infectious or malignant disorders; Beta-Pso
Résumé :
[en] Psoriasis patients carry an increased risk for associated comorbidities. Dermatologists have to be aware of the effects of systemic treatments not only on psoriasis but also on co-occurring diseases. In case of other coexisting inflammatory diseases, the right psoriasis treatment may improve both disorders. For infectious and malignant idsorders, some treatments have to be avoided as they may be harmful.
Disciplines :
Dermatologie
Auteur, co-auteur :
Lambert, J.L.W; Ghent University Hospital, Ghent, Belgium > Department of Dermatology
Segaert, S.; Private Practice, Tremelo, Belgium
Ghislain, P.D; Univeristé Catholique de Louvain > Cliniques Saint-Luc
Hillary, T.; University Hospital Leuven, Leuven, Belgium
NIKKELS, Arjen ; Centre Hospitalier Universitaire de Liège - CHU > Autres Services Médicaux > Service de dermatologie
Willaert, F.; Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium
Lambert, J.; University Hospital of Antwerp, Antwerp, Belgium > Dermatology
Speeckaert, R.
Langue du document :
Anglais
Titre :
Practical recommendations for systemic treatment in psoriasis in case of coexisting inflammatory, neurologic, infectious, or malignant disorders (BETA-PSO: Belgian Evidence-based Treatment Advice in Psoriasis; part 2)
Titre traduit :
[en] Recommandations pratiques pour le traitement systémique du psoriasis en cas de coexistence des troubles inflammatoires, neurologiques, infectieux ou malins (BETA-PSO: Belgian Evidence-based Treatment Advice in Psoriasis; partie 2)
Date de publication/diffusion :
2020
Titre du périodique :
Journal of the European Academy of Dermatology and Venereology
Zachariae H. Prevalence of joint disease in patients with psoriasis: implications for therapy. Am J Clin Dermatol 2003; 4: 441–447.
Fu Y, Lee C-H, Chi C-C. Association of psoriasis with inflammatory bowel disease: a systematic review and meta-analysis. JAMA Dermatol 2018; 154: 1417–1423.
Ma C, Panaccione R, Khanna R, Feagan BG, Jairath V. IL12/23 or selective IL23 inhibition for the management of moderate-to-severe Crohn's disease? Best Pract Res Clin Gastroenterol 2019; 38–39: 101604.
Hueber W, Sands BE, Lewitzky S et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 2012; 61: 1693–1700.
Hohenberger M, Cardwell LA, Oussedik E, Feldman SR. Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease. J Dermatolog Treat 2018; 29: 13–18.
Emond B, Ellis LA, Chakravarty SD, Ladouceur M, Lefebvre P. Real-world incidence of inflammatory bowel disease among patients with other chronic inflammatory diseases treated with interleukin-17a or phosphodiesterase 4 inhibitors. Curr Med Res Opin 2019; 35: 1751–1759.
Silfvast-Kaiser AS, Homan KB, Mansouri B. A narrative review of psoriasis and multiple sclerosis: links and risks. Psoriasis (Auckl) 2019; 9: 81–90.
Trafford AM, Parisi R, Kontopantelis E, Griffiths CEM, Ashcroft DM. Association of psoriasis with the risk of developing or dying of cancer: a systematic review and meta-analysis. JAMA Dermatol 2019; 155: 1390.
Geller S, Xu H, Lebwohl M, Nardone B, Lacouture ME, Kheterpal M. Malignancy risk and recurrence with psoriasis and its treatments: a concise update. Am J Clin Dermatol 2018; 19: 363–375.
Singh JA, Guyatt G, Ogdie A et al. Special article: 2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis. Arthritis Rheumatol 2019; 71: 5–32.
Sakkas LI, Zafiriou E, Bogdanos DP. Mini review: new treatments in psoriatic arthritis. Focus on the IL-23/17 axis. Front Pharmacol 2019; 10: 872.
Oh EH, Koh WS, Shin JM, Kim JE, Ko JY, Ro YS. Clinical experience of cyclosporin treatment in patients with psoriasis and psoriatic arthritis. J Dermatol 2018; 45: 329–330.
Olivieri I, Salvarani C, Cantini F et al. Therapy with cyclosporine in psoriatic arthritis. Semin Arthritis Rheum 1997; 27: 36–43.
Peeters AJ, Dijkmans BA, Van der schroeff JG. Fumaric acid therapy for psoriatic arthritis. A randomized, double-blind, placebo-controlled study. Br J Rheumatol 1992; 31: 502–504.
Whitlock SM, Enos CW, Armstrong AW et al. Management of psoriasis in patients with inflammatory bowel disease: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 2018; 78: 383–394.
Wong U, Cross RK. Expert opinion on interleukin-12/23 and interleukin-23 antagonists as potential therapeutic options for the treatment of inflammatory bowel disease. Expert Opin Investig Drugs 2019; 28: 473–479.
Suleiman AA, Khatri A, Minocha M, Othman AA. Population pharmacokinetics of the interleukin-23 inhibitor risankizumab in subjects with psoriasis and Crohn's disease: analyses of phase I and II trials. Clin Pharmacokinet 2019; 58: 375–387.
Iriarte A, Zaera C, Bachiller-Corral J, López-Sanromán A. Inflammatory bowel disease as a paradoxical effect of anti-TNF alpha therapy. Gastroenterol Hepatol 2017; 40: 117–121.
Knyazev OV, Kagramanova AV, Lishchinskaya AA et al. Efficacy and tolerability of certolizumab pegol in Crohn's disease in clinical practice. Ter Arkh 2018; 90: 74–80.
Ahmed Z, Venkata K, Zhang N, Malik TA. Comparative effectiveness of ustekinumab versus adalimumab in induction of clinical response and remission in Crohn's disease: experience of a real-world cohort at a tertiary care inflammatory bowel disease referral center. Gastroenterology Res 2019; 12: 245–251.
Danese S, Neurath MF, Kopoń A et al. Effects of apremilast, an oral inhibitor of phosphodiesterase 4, in a randomized trial of patients with active ulcerative colitis. Clin Gastroenterol Hepatol 2020; 18. https://doi.org/10.1016/j.cgh.2019.12.032
Korzenik J, Larsen MD, Nielsen J, Kjeldsen J, Nørgård BM. Increased risk of developing Crohn's disease or ulcerative colitis in 17 018 patients while under treatment with anti-TNFα agents, particularly etanercept, for autoimmune diseases other than inflammatory bowel disease. Aliment Pharmacol Ther 2019; 50: 289–294.
Targan SR, Feagan B, Vermeire S et al. A randomized, double-blind, placebo-controlled phase 2 study of brodalumab in patients with moderate-to-severe Crohn's disease. Am J Gastroenterol 2016; 111: 1599–1607.
Marrie RA, Patten SB, Tremlett H, Wolfson C, Leung S, Fisk JD. Increased incidence and prevalence of psoriasis in multiple sclerosis. Mult Scler Relat Disord 2017; 13: 81–86.
Segal BM, Constantinescu CS, Raychaudhuri A et al. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol 2008; 7: 796–804.
Havrdová E, Belova A, Goloborodko A et al. Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study. J Neurol 2016; 263: 1287–1295.
Venturini M, Zanca A, Venturuzzo A et al. Secukinumab for patients with plaque psoriasis affected by multiple sclerosis: a mini-review with a representative case report. J Eur Acad Dermatol Venereol 2020; 34: e110–e112.
Macaluso F, Guggino G, Mauro D, Rizzo C, Bignone R, Ciccia F. Safety and efficacy of secukinumab treatment in a patient with ankylosing spondylitis and concomitant multiple sclerosis. Clin Exp Rheumatol 2019; 37: 1096.
Gray O, McDonnell GV, Forbes RB. Methotrexate for multiple sclerosis. Cochrane Database Syst Rev 2004: CD003208.
Ashtari F, Savoj MR. Effects of low dose methotrexate on relapsing-remitting multiple sclerosis in comparison to Interferon β-1α: a randomized controlled trial. J Res Med Sci 2011; 16: 457–462.
Honda Y, Otsuka A, Egawa G et al. Multiple neurological abnormalities, including pontine hemorrhage, multiple sclerosis and aseptic meningitis, during anti-TNF-α therapy in psoriatic arthritis. Eur J Dermatol 2015; 25: 487–488.
Humira 40 mg solution for injection in pre-filled syringe - Summary of Product Characteristics (SmPC) - (emc). URL https://www.medicines.org.uk/emc/product/2150/smpc (last accessed: 25 January 2020).
Enbrel 25 mg powder and solvent for solution for injection - Summary of Product Characteristics (SmPC) - (emc). URL https://www.medicines.org.uk/emc/product/3837/smpc (last accessed: 25 January 2020).
Cimzia 200 mg solution for injection in pre-filled syringe - Summary of Product Characteristics (SmPC) - (emc). URL https://www.medicines.org.uk/emc/product/4450/smpc (last accessed: 25 January 2020).
Remicade 100mg powder for concentrate for solution for infusion - Summary of Product Characteristics (SmPC) - (emc). URL https://www.medicines.org.uk/emc/product/3831/smpc#POSOLOGY (last accessed: 25 January 2020).
Etminan M, Sodhi M, Samii A, Carleton BC, Kezouh A, Antonio Avina-Zubieta J. Tumor necrosis factor inhibitors and risk of peripheral neuropathy in patients with rheumatic diseases. Semin Arthritis Rheum 2019; 48: 1083–1086.
Reddy SP, Shah VV, Wu JJ. Apremilast for a psoriasis patient with HIV and hepatitis C. J Eur Acad Dermatol Venereol 2017; 31: e481–e482.
Lee CS, Li K. A review of acitretin for the treatment of psoriasis. Expert Opin Drug Saf 2009; 8: 769–779.
Nakamura M, Abrouk M, Farahnik B, Zhu TH, Bhutani T. Psoriasis treatment in HIV-positive patients: a systematic review of systemic immunosuppressive therapies. Cutis 2018; 101: 38; 42; 56.
Methotrexate 2.5 mg Tablets - Summary of Product Characteristics (SmPC) - (emc). URL https://www.medicines.org.uk/emc/product/511/smpc (last accessed: 25 January 2020).
Neoral Soft Gelatin Capsules - Summary of Product Characteristics (SmPC) - (emc). URL https://www.medicines.org.uk/emc/product/1034/smpc(last accessed: 25 January 2020).
Nast A, Spuls PI, van der Kraaij G et al. European S3-guideline on the systemic treatment of psoriasis vulgaris - update apremilast and secukinumab - EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol 2017; 31: 1951–1963.
Couderc S, Lapeyre-Mestre M, Bourrel R, Paul C, Montastruc J-L, Sommet A. Infectious risk of biological drugs vs. traditional systemic treatments in moderate-to-severe psoriasis: a cohort analysis in the French insurance database. Fundam Clin Pharmacol 2018; 32: 436–449.
Velázquez Tarjuelo D, de la Cueva Dobao P. Certolizumab in a patient with severe psoriasis and concomitant hepatitis C virus infection. JAAD Case Rep 2018; 4: 833–834.
Oniankitan O, Duvoux C, Challine D et al. Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C. J Rheumatol 2004; 31: 107–109.
Piaserico S, Messina F, Russo FP. Managing psoriasis in patients with HBV or HCV infection: practical considerations. Am J Clin Dermatol 2019; 20: 829–845.
Galluzzo M, D'Adamio S, Silvaggio D et al. Ustekinumab treatment for moderate-to-severe plaque psoriasis: eight-year real-life experience. Expert Opin Biol Ther 2020; 20: 95–104.
Young MS, Horn EJ, Cather JC. The ACCEPT study: ustekinumab versus etanercept in moderate-to-severe psoriasis patients. Expert Rev Clin Immunol 2011; 7: 9–13.
Klintmalm GBG, Iwatsuki S, Starzl TE. Cyclosporin A hepatotxicity in 66 renal allograft recipients. Transplantation 1981; 32: 488–489.
Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol 2019; 80: 27–40.
Acitretin 25mg Capsules - Summary of Product Characteristics (SmPC) - (emc). URL https://www.medicines.org.uk/emc/product/5264/smpc (last accessed: 25 January 2020).
Chiu H-Y, Hui RC-Y, Huang Y-H et al. Safety profile of secukinumab in treatment of patients with psoriasis and concurrent hepatitis B or C: a multicentric prospective cohort study. Acta Derm Venereol 2018; 98: 829–834.
Crowley J, Thaçi D, Joly P et al. Long-term safety and tolerability of apremilast in patients with psoriasis: pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2). J Am Acad Dermatol 2017; 77: 310–317.e1.
Bonifati C, Lora V, Graceffa D, Nosotti L. Management of psoriasis patients with hepatitis B or hepatitis C virus infection. World J Gastroenterol 2016; 22: 6444–6455.
Pauly MP, Tucker L-Y, Szpakowski J-L et al. Incidence of hepatitis B virus reactivation and hepatotoxicity in patients receiving long-term treatment with tumor necrosis factor antagonists. Clin Gastroenterol Hepatol 2018; 16: 1964–1973.e1.
Chiu Y-M, Lai M-S, Chan KA. Assessing risk of liver enzyme elevation in patients with immune-mediated diseases and different hepatitis B virus serostatus receiving anti-TNF agents: a nested case-control study. Arthritis Res Ther 2017; 19: 214.
Fernández-Ruiz M. Assessment of latent infections in patients receiving biological therapies. Rev Esp Quimioter 2019; 32(Suppl 2): 63–68.
Diak P, Siegel J, Grenade LL, Choi L, Lemery S, McMahon A. Tumor necrosis factor α blockers and malignancy in children: forty-eight cases reported to the food and drug administration. Arthritis Rheum 2010; 62: 2517–2524.
Halkier-Sørensen L, Laurberg G, Andresen J. Bone changes in children on long-term treatment with etretinate. J Am Acad Dermatol 1987; 16(5 Pt 1): 999–1006.
van Geel MJ, van de Kerkhof PCM, Oostveen AM, de Jong EMGJ, Seyger MMB. Fumaric acid esters in recalcitrant pediatric psoriasis: a prospective, daily clinical practice case series. J Dermatolog Treat 2016; 27: 214–220.
Ribero S, Licciardello M, Quaglino P, Dapavo P. Efficacy and safety of secukinumab in patients with plaque psoriasis and latent tuberculosis. Case Rep Dermatol 2019; 11(Suppl 1): 23–28.
Romiti R, Valenzuela F, Chouela EN et al. Prevalence and outcome of latent tuberculosis in patients receiving ixekizumab: integrated safety analysis from 11 clinical trials of patients with plaque psoriasis. Br J Dermatol 2019; 181: 202–203.
Crowley JJ, Warren RB, Cather JC. Safety of selective IL-23p19 inhibitors for the treatment of psoriasis. J Eur Acad Dermatol Venereol 2019; 33: 1676–1684.
Galluzzo M, D'Adamio S, Silvaggio D, Lombardo P, Bianchi L, Talamonti M. In which patients the best efficacy of secukinumab? Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-severe plaque psoriasis. Expert Opin Biol Ther 2020; 20: 173–182.
Chiu Y-M, Tang C-H, Hung S-T, Yang Y-W, Fang C-H, Lin H-Y. A real-world risk analysis of biological treatment (adalimumab and etanercept) in a country with a high prevalence of tuberculosis and chronic liver disease: a nationwide population-based study. Scand J Rheumatol 2017; 46: 236–240.
Rademaker M, Rubel DM, Agnew K et al. Psoriasis and cancer. An Australian/New Zealand narrative. Australas J Dermatol 2019; 60: 12–18.
Smith CH, Jabbar-Lopez ZK, Yiu ZZ et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. Br J Dermatol 2017; 177: 628–636.
Hojo M, Morimoto T, Maluccio M et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999; 397: 530–534.
Kahn JS, Casseres RG, Her MJ, Dumont N, Gottlieb AB, Rosmarin D. Treatment of psoriasis with biologics and apremilast in patients with a history of malignancy: a retrospective chart review. J Drugs Dermatol 2019; 18.
Apalla Z, Psarakis E, Lallas A, Koukouthaki A, Fassas A, Smaragdi M. Psoriasis in patients with active lung cancer: is apremilast a safe option? Dermatol Pract Concept 2019; 9: 300–301.
Egeberg A, Thyssen JP, Gislason GH, Skov L. Skin cancer in patients with psoriasis. J Eur Acad Dermatol Venereol 2016; 30: 1349–1353.
Paradisi A, Didona B, Tabolli S et al. Reduced frequency of non-melanoma skin cancer in 72,739 patients with psoriasis: a retrospective study. Eur J Dermatol 2017; 27: 359–362.
Bettoli V, Zauli S Virgili A. Retinoids in the chemoprevention of non-melanoma skin cancers: why, when and how. J Dermatolog Treat 2013; 24: 235–237.
Bavinck JN, Tieben LM, Van der Woude FJ et al. Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: a double-blind, placebo-controlled study. J Clin Oncol 1995; 13: 1933–1938.
Cheeley J, Sahn RE, DeLong LK, Parker SR. Acitretin for the treatment of cutaneous T-cell lymphoma. J Am Acad Dermatol 2013; 68: 247–254.
Peleva E, Exton LS, Kelley K, Kleyn CE, Mason KJ, Smith CH. Risk of cancer in patients with psoriasis on biological therapies: a systematic review. Br J Dermatol 2018; 178: 103–113.
Polesie S, Gillstedt M, Paoli J, Osmancevic A. Methotrexate and melanoma-specific mortality. J Eur Acad Dermatol Venereol 2019; 33: e123–e125.
Polesie S, Gillstedt M, Paoli J, Osmancevic A. Methotrexate exposure and risk of cutaneous malignant melanoma: no evidence of a dose-response relationship. Acta Derm Venereol 2018; 98: 888–895.
Kaluzki I, Hrgovic I, Hailemariam-Jahn T et al. Dimethylfumarate inhibits melanoma cell proliferation via p21 and p53 induction and bcl-2 and cyclin B1 downregulation. Tumour Biol 2016; 37: 13627–13635.
Liu X, Chan SY, Ho PC-L. Comparison of the in vitro and in vivo effects of retinoids either alone or in combination with cisplatin and 5-fluorouracil on tumor development and metastasis of melanoma. Cancer Chemother Pharmacol 2008; 63: 167–174.
Nardone B, Hammel JA, Raisch DW, Weaver LL, Schneider D, West DP. Melanoma associated with tumour necrosis factor-α inhibitors: a Research on Adverse Drug events And Reports (RADAR) project. Br J Dermatol 2014; 170: 1170–1172.
Safa G, Fromentoux S, Darrieux L, Hogenhuis J-A, Tisseau L. Nodal melanoma metastasis under infliximab therapy in a patient with nevoid melanoma first misdiagnosed as benign nevus: a potentially dangerous diagnostic pitfall in the era of biologic therapies. Case Rep Dermatol 2013; 5: 290–294.
Marasini B, Cozzaglio L, Belloli L, Massarotti M, Ughi N, Pedrazzoli P. Metastatic melanoma in a young woman treated with TNF-α inhibitor for psoriatic arthritis: a case report. Curr Drug Saf 2011; 6: 275–276.
Papp K, Gottlieb AB, Naldi L et al. Safety surveillance for ustekinumab and other psoriasis treatments from the psoriasis longitudinal assessment and registry (PSOLAR). J Drugs Dermatol 2015; 14: 706–714.
Ghazanfar MN, Karlsmark T, Danielsen PL, Thomsen SF. Sequential treatment with secukinumab and ustekinumab in a patient with severe psoriasis and recent history of cerebral malignant melanoma metastasis. Clin Case Rep 2019; 7: 1350–1351.
Salopek TG. Recurrence of melanoma after starting apremilast for psoriasis. Case Rep Dermatol 2017; 9: 108–111.
Vitiello GA, Miller G. Targeting the interleukin-17 immune axis for cancer immunotherapy. J Exp Med 2019; 217: e20190456.
